Shekar N. Kurpad

Shekar N. Kurpad

Auto-generated profile, based on publicly available information

Shekar N. Kurpad

Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2023 in Journal of Neurotrauma
Verified
Journal Article
Open access
Michael FehlingsMichael Fehlings
Michael Fehlings
AMAli Moghaddamjou
Ali Moghaddamjou
JHJames S Harrop
James S Harrop
RSRalph Stanford
Ralph Stanford
JBJonathon Robert Ball
Jonathon Robert Ball
BKBranko Kopjar
Branko Kopjar
Riluzole is a sodium-glutamate antagonist that attenuates neurodegeneration in amyotrophic lateral sclerosis (ALS). It has shown favorable results in promoting recovery in pre-clinical models of traumatic spinal cord injury (tSCI) and in early phase clinical trials. This study aimed to evaluate the efficacy and safety of riluzole in acute cervical tSCI. An international, multi-center, prospective, randomized, double-blinded, placebo-controlled, adaptive, Phase III trial (NCT01597518) was undertaken. Patients with American Spinal Injury Association Impairment Scale (AIS) A-C, cervical (C4-C8) tSCI, and <12 h from injury were randomized to receive either riluzole, at an oral dose of 100 mg twice per day (BID) for the first 24 h followed by 50 mg BID for the following 13 days, or placebo. The primary efficacy end-point was change in Upper Extremity Motor (UEM) scores at 180 days. The primary efficacy analyses were conducted on an intention to treat (ITT) and completed cases (CC) basis. The study was powered at a planned enrolment of 351 patients. The trial began in October 2013 and was halted by the sponsor on May 2020 (and terminated in April 2021) in the face of the global COVID-19 pandemic. One hundred ninety-three patients (54.9% of the pre-planned enrolment) were randomized with a follow-up rate of 82.7% at 180 days. At 180 days, in the CC population the riluzole-treated patients compared with placebo had a mean gain of 1.76 UEM scores (95% confidence interval: -2.54-6.06) and 2.86 total motor scores (CI: -6.79-12.52). No drug-related serious adverse events were associated with the use of riluzole. Additional pre-planned sensitivity analyses revealed that in the AIS C population, riluzole was associated with significant improvement in total motor scores (estimate: standard error [SE] 8.0; CI 1.5-14.4) and upper extremity motor scores (SE 13.8; CI 3.1-24.5) at 6 months. AIS B patients had higher reported independence, measured by the Spinal Cord Independence Measure score (45.3 vs. 27.3; d: 18.0 CI: -1.7-38.0) and change in mental health scores, measured by the Short Form 36 mental health domain (2.01 vs. -11.58; d: 13.2 CI: 1.2-24.8) at 180 days. AIS A patients who received riluzole had a higher average gain in neurological levels at 6 months compared with placebo (mean 0.50 levels gained vs. 0.12 in placebo; d: 0.38, CI: -0.2-0.9). The primary analysis did not achieve the predetermined end-point of efficacy for riluzole, likely related to insufficient power. However, on pre-planned secondary analyses, all subgroups of cervical SCI subjects (AIS grades A, B and C) treated with riluzole showed significant gains in functional recovery. The results of this trial may warrant further investigation to extend these findings. Moreover, guideline development groups may wish to assess the possible clinical relevance of the secondary outcome analyses, in light of the fact that SCI is an uncommon orphan disorder without an accepted neuroprotective treatment.

1 January 2014 in Neurosurgery
Verified
Journal Article
Open access
PDF file
AVAditya Vedantam
Aditya Vedantam
MJMichael B. Jirjis
Michael B. Jirjis
BSBrian D. Schmit
Brian D. Schmit
MWMarjorie C. Wang
Marjorie C. Wang
JUJohn L. Ulmer
John L. Ulmer
SKShekar N. Kurpad
Shekar N. Kurpad
Diffusion tensor imaging (DTI) provides a measure of the directional diffusion of water molecules in tissues. The measurement of DTI indexes within th

1 May 2015 in World Neurosurgery
Verified
Journal Article
Closed access
AVAditya Vedantam
Aditya Vedantam
GEGerald Eckardt
Gerald Eckardt
MWMarjorie C. Wang
Marjorie C. Wang
BSBrian D. Schmit
Brian D. Schmit
SKShekar N. Kurpad
Shekar N. Kurpad

6 February 2013 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
AVAditya Vedantam
Aditya Vedantam
MJMichael B. Jirjis
Michael B. Jirjis
BSBrian D. Schmit
Brian D. Schmit
MWMarjorie C. Wang
Marjorie C. Wang
JUJohn L. Ulmer
John L. Ulmer
SKShekar N. Kurpad
Shekar N. Kurpad
Purpose: To characterize diffusion tensor imaging (DTI) metrics across all levels of the cervical spinal cord (CSC) and to study the impact of age and signal quality on these metrics.Materials and Methods: DTI metrics were calculated for gray matter (GM) and white matter (WM) funiculi throughout the CSC (C1–T1) in 25 healthy subjects (22‐85 years old). Signal‐to‐noise ratios (SNRs) and mean DTI metrics were measured for the upper (C1‐3), middle (C4‐6) and lower (C7‐T1) cervical segments. Age‐related changes in DTI metrics were analyzed for the individual segment groups.Results: Fractional anisotropy (FA), mean diffusivity (MD) and transverse apparent diffusion coefficient (tADC) showed significant differences between GM and WM funiculi. Significant age‐related changes were observed in FA in upper and middle CSC segments but not in the lower CSC. The median SNR was significantly lower in the middle and lower segment groups as compared to the upper levels, contributing to poor spatial resolution in these regions.Conclusion: This study provides DTI data for GM and WM funiculi throughout the CSC. While DTI metrics may be used to define cord pathology, variations in metrics due to age and signal quality need to be accounted for before making definitive conclusions. J. Magn. Reson. Imaging 2013;38:861–867.

1 January 2017 in World Neurosurgery
Verified
Journal Article
Closed access
AVAditya Vedantam
Aditya Vedantam
ARAvinash Rao
Avinash Rao
SKShekar N. Kurpad
Shekar N. Kurpad
MJMichael B. Jirjis
Michael B. Jirjis
GEGerald Eckardt
Gerald Eckardt
MWMarjorie C. Wang
Marjorie C. Wang

23 February 2018 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
ARAvinash Rao
Avinash Rao
HSHesham Soliman
Hesham Soliman
MKMayank Kaushal
Mayank Kaushal
OMOlesya Motovylyak
Olesya Motovylyak
AVAditya Vedantam
Aditya Vedantam
SKShekar N Kurpad
Shekar N Kurpad
BACKGROUND: Fractional anisotropy (FA) of the high cervical cord correlates with upper limb function in acute cervical cord injury. We investigated the correlation between preoperative FA at the level of maximal compression and functional recovery in a group of patients after decompressive surgery for cervical spondylotic myelopathy (CSM). OBJECTIVE: To determine the usefulness of FA as a biomarker for severity of CSM and as a prognostic biomarker for improvement after surgery. METHODS: Patients received diffusion tensor imaging (DTI) scans preoperatively. FA values of the whole cord cross-section at the level of maximal compression and upper cervical cord (C1-2) were calculated. Functional status was measured using the modified Japanese Orthopedic Association (mJOA) scale preoperatively and at follow-up up to 2 yr. Regression analysis between FA and mJOA was performed. DTI at C4-7 was obtained in controls. RESULTS: Forty-four CSM patients enrolled prior to decompression were compared with 24 controls. FA at the level of maximal compression correlated positively with preoperative mJOA score. Preoperative FA correlated inversely with recovery throughout the postoperative period. This was statistically significant at 12 mo postoperation and nearly so at 6 and 24 mo. Patients with preoperative FA 0.55. CONCLUSION: In the largest longitudinal study of this kind, FA promises a valid biomarker for severity of CSM and postoperative improvement. FA is an objective measure of function and could provide a basis for prognosis. FA is particularly useful if preoperative values are less than 0.55.